6.
Stevens T, Morlote D, Xiu J, Swensen J, Brandwein-Weber M, Miettinen M
. NUTM1-rearranged neoplasia: a multi-institution experience yields novel fusion partners and expands the histologic spectrum. Mod Pathol. 2019; 32(6):764-773.
PMC: 8194366.
DOI: 10.1038/s41379-019-0206-z.
View
7.
French C, Miyoshi I, Kubonishi I, Grier H, Perez-Atayde A, Fletcher J
. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003; 63(2):304-7.
View
8.
Alekseyenko A, Walsh E, Zee B, Pakozdi T, Hsi P, Lemieux M
. Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma. Proc Natl Acad Sci U S A. 2017; 114(21):E4184-E4192.
PMC: 5448232.
DOI: 10.1073/pnas.1702086114.
View
9.
Bishop J, French C, Ali S
. Cytopathologic features of NUT midline carcinoma: A series of 26 specimens from 13 patients. Cancer Cytopathol. 2016; 124(12):901-908.
DOI: 10.1002/cncy.21761.
View
10.
Haack H, Johnson L, Fry C, Crosby K, Polakiewicz R, Stelow E
. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol. 2009; 33(7):984-91.
PMC: 2783402.
DOI: 10.1097/PAS.0b013e318198d666.
View
11.
Huang Q, He L, Zheng S, Liu T, Peng B
. An Overview of Molecular Mechanism, Clinicopathological Factors, and Treatment in NUT Carcinoma. Biomed Res Int. 2019; 2019:1018439.
PMC: 6877965.
DOI: 10.1155/2019/1018439.
View
12.
Grayson A, Walsh E, Cameron M, Godec J, Ashworth T, Ambrose J
. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene. 2013; 33(13):1736-1742.
PMC: 3942361.
DOI: 10.1038/onc.2013.126.
View
13.
Kubonishi I, Takehara N, Iwata J, Sonobe H, Ohtsuki Y, Abe T
. Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma. Cancer Res. 1991; 51(12):3327-8.
View
14.
French C
. NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment. Pathol Int. 2018; 68(11):583-595.
DOI: 10.1111/pin.12727.
View
15.
Stathis A, Zucca E, Bekradda M, Gomez-Roca C, Delord J, de La Motte Rouge T
. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. Cancer Discov. 2016; 6(5):492-500.
PMC: 4854801.
DOI: 10.1158/2159-8290.CD-15-1335.
View
16.
Huang Z, Wen W, Mao W
. [Comprehensive treatment strategies for head neck tumors]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2023; 37(9):673-690.
PMC: 10722124.
DOI: 10.13201/j.issn.2096-7993.2023.09.001.
View
17.
Tu X, Ren J, Zhao Y
. [Advances in risk factors and genetic risk of head and neck squamous cell carcinoma]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022; 36(5):391-396.
PMC: 10128266.
DOI: 10.13201/j.issn.2096-7993.2022.05.015.
View
18.
Lee T, Cho J, Baek C, Son Y, Jeong H, Chung M
. Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review. Head Neck. 2020; 42(5):924-938.
DOI: 10.1002/hed.26067.
View
19.
Shiota H, Elya J, Alekseyenko A, Chou P, Gorman S, Barbash O
. "Z4" Complex Member Fusions in NUT Carcinoma: Implications for a Novel Oncogenic Mechanism. Mol Cancer Res. 2018; 16(12):1826-1833.
PMC: 6279489.
DOI: 10.1158/1541-7786.MCR-18-0474.
View
20.
Mengoli M, Longo F, Fraggetta F, Cavazza A, Dubini A, Ali G
. The 2015 World Health Organization Classification of lung tumors: new entities since the 2004 Classification. Pathologica. 2018; 110(1):39-67.
View